Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
about
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer VaccineApproaches to modernize the combination drug development paradigmEvidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckAnti-Epileptic Drug Combination Efficacy in an In Vitro Seizure Model - Phenytoin and Valproate, Lamotrigine and Valproate.The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapySynergistic antitumor efficacy of antibacterial helvolic acid from Cordyceps taii and cyclophosphamide in a tumor mouse model.TH9 cells in anti-tumor immunity.SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice.Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer.Laricitrin ameliorates lung cancer-mediated dendritic cell suppression by inhibiting signal transducer and activator of transcription 3Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.Combine and conquer: challenges for targeted therapy combinations in early phase trials.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseProspects and progress of atezolizumab in non-small cell lung cancer.Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study.Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer.Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model.Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.Fate of Antibody-Drug Conjugates in Cancer Cells.Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration.Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab.Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents.Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.Immunotherapy in the Asiatic population: any differences from Caucasian population?Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms.Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination StrategiesCombatting mucosal melanoma: recent advances and future perspectives
P2860
Q26741101-9DC24940-3355-4ECB-AA00-59FD2A58EE71Q26782583-6F061235-1089-48D3-A0A1-81DF19E2BD93Q28072074-F2ED0B88-3D67-4891-85D1-F02E8C6745A2Q33650470-5C3E9D52-BEB7-4343-829A-8E1439FFBF75Q36246287-32C05D2E-C2F9-461A-A901-4439E0A55551Q37376414-05402541-EBA5-49C1-B28D-C4123BC26B2FQ37514733-F3B3E2E2-326D-4F31-B55C-B8D0500D115EQ37575177-AC5354A9-A77A-4573-BFB0-814C2DDD7D7AQ37580265-EA5B8103-3E68-42C8-B6B7-FD24D51AF9B6Q37709102-2C8DB1E5-5024-4354-844C-FE80F3FCC098Q37709119-8EAC4E23-4ACE-4613-8F2C-8E90E89F02A0Q37739214-FE5CF61A-D2C7-47EB-AE49-C3B01A7D7BC7Q38680348-90A41216-A94C-40BF-8BC3-70C275CFAE75Q38733637-E639C374-BEE4-474C-B00A-0666AA3C96B6Q38734451-9B281248-77A7-427E-8A61-0B78D8E4BB57Q38831232-22B2CA3D-563F-46CE-B80F-DF8D49AE83D3Q38881814-01D5DEFC-083E-49F4-86D4-C72CF0F6590EQ38961442-1F3375F3-DAA3-4356-8DAF-839C57CC0E9AQ41078784-D282579E-4EF5-41B4-A39A-604628CB536FQ42378707-ADE7302D-2785-450E-9C3B-94833CE790E3Q47192770-26F05FEC-5717-4264-BF9A-8E2EF3796037Q48238878-EB97C872-5354-4E53-8FF0-A681871B6008Q48263650-8CFF7E5B-AB18-482E-8822-B06A1F7454E7Q49883378-912419C1-D634-4ED1-8993-5341EBD2EA66Q50089433-BC894905-0DFF-48F3-B06F-F274CC024C8AQ50731156-CA17BCFA-E4B5-4C89-B1BD-BEF93BA8B597Q51157837-733C8424-F16A-41E0-9BFF-14618C33AF10Q53121293-6218C4CE-FBB1-411D-8A5F-427FC5C33278Q55288740-6A3DDC3D-6B1F-493F-B388-E95CFF8EC59DQ55312983-F50FAE47-250B-4118-AE93-31F0DBA8C2FAQ55515330-65B4FB35-9DFF-47FB-9F9D-6773AA4CAEB3Q58795231-0FCB61FB-58C9-4474-9582-894622D04BD1Q59126427-2B5480F0-43E1-4B47-A62D-323C967E104B
P2860
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
@en
type
label
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
@en
prefLabel
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
@en
P2860
P50
P356
P1433
P1476
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDV209
P577
2015-04-28T00:00:00Z